Jonathan Berman, Partner, Jones Day to Speak at the Knowledge Groups Product-Hopping in the Pharmaceutical Industry: Antitrust Issues to Watch for in 2016 Live Webcast
Summary
Jonathans antitrust docket has included cases involving allegations of product-hopping, pay-for-delay, and price-fixing, government challenges to mergers, exclusive contracts, and a variety of rule-of-reason and monopolization theories.Event Synopsis: One of the antitrust issues expected to surge the drug industry this 2016 is the legal developments concerning the practice of product-hopping or “forced switching.” The U.S. government is getting critical in this tactic which thwarts generic competition.The appellate decision in a related case upheld the injunction which requires the continued availability of an older drug until generic entry, after the introduction of the drug’s new version.Jonathan also has advised clients, on dozens of matters, regarding FDA law and practice.Jonathans antitrust docket has included cases involving allegations of product-hopping, pay-for-delay, and price-fixing, government challenges to mergers, exclusive contracts, and a variety of rule-of-reason and monopolization theories.The appellate decision in a related case upheld the injunction which requires the continued availability of an older drug until generic entry, after the introduction of the drug’s new version.